Jupiter Asset Management Ltd. Has $13.73 Million Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD

Jupiter Asset Management Ltd. grew its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 56.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 636,375 shares of the biopharmaceutical company’s stock after acquiring an additional 229,324 shares during the period. Jupiter Asset Management Ltd. owned 0.38% of ACADIA Pharmaceuticals worth $13,727,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Picton Mahoney Asset Management bought a new position in ACADIA Pharmaceuticals in the first quarter valued at approximately $32,000. Banque Transatlantique SA acquired a new stake in shares of ACADIA Pharmaceuticals in the 1st quarter valued at approximately $31,000. Federated Hermes Inc. grew its stake in shares of ACADIA Pharmaceuticals by 231.5% in the first quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 1,618 shares in the last quarter. Quantbot Technologies LP acquired a new position in ACADIA Pharmaceuticals during the first quarter worth $52,000. Finally, PNC Financial Services Group Inc. increased its holdings in ACADIA Pharmaceuticals by 545.8% during the first quarter. PNC Financial Services Group Inc. now owns 5,438 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 4,596 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

Insider Transactions at ACADIA Pharmaceuticals

In other news, Director James M. Daly sold 30,000 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $22.37, for a total value of $671,100.00. Following the completion of the sale, the director directly owned 4,041 shares in the company, valued at approximately $90,397.17. The trade was a 88.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Elizabeth A. Garofalo sold 1,600 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $25.98, for a total transaction of $41,568.00. Following the sale, the director directly owned 25,382 shares of the company’s stock, valued at approximately $659,424.36. This trade represents a 5.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 57,098 shares of company stock valued at $1,349,356. 28.30% of the stock is currently owned by company insiders.

ACADIA Pharmaceuticals Stock Up 1.7%

Shares of NASDAQ:ACAD opened at $24.13 on Thursday. The stock has a market cap of $4.08 billion, a PE ratio of 18.14, a P/E/G ratio of 7.90 and a beta of 0.80. The business has a 50 day moving average of $22.48 and a 200-day moving average of $22.13. ACADIA Pharmaceuticals Inc. has a 12-month low of $13.40 and a 12-month high of $26.65.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.14 by $0.28. ACADIA Pharmaceuticals had a net margin of 21.80% and a return on equity of 14.69%. The business had revenue of $278.63 million for the quarter, compared to the consensus estimate of $276.52 million. During the same period in the prior year, the company posted $0.20 earnings per share. ACADIA Pharmaceuticals’s revenue was up 11.3% compared to the same quarter last year. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts expect that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on ACAD shares. Wall Street Zen upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. UBS Group raised their target price on shares of ACADIA Pharmaceuticals from $36.00 to $39.00 and gave the company a “buy” rating in a research note on Tuesday, September 9th. JPMorgan Chase & Co. reduced their price target on ACADIA Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Monday, September 29th. Mizuho upped their price objective on ACADIA Pharmaceuticals from $23.00 to $24.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Finally, Needham & Company LLC raised their price objective on ACADIA Pharmaceuticals from $28.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $28.94.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.